Supernus Pharmaceuticals/$SUPN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Supernus Pharmaceuticals
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
Ticker
$SUPN
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
674
ISIN
US8684591089
Website
SUPN Metrics
BasicAdvanced
$2.1B
29.78
$1.11
0.74
-
Price and volume
Market cap
$2.1B
Beta
0.74
52-week high
$40.28
52-week low
$25.55
Average daily volume
523K
Financial strength
Current ratio
2.44
Quick ratio
2.162
Long term debt to equity
2.558
Total debt to equity
3.134
Profitability
EBITDA (TTM)
138.656
Gross margin (TTM)
88.42%
Net profit margin (TTM)
9.27%
Operating margin (TTM)
8.77%
Effective tax rate (TTM)
32.55%
Revenue per employee (TTM)
$990,000
Management effectiveness
Return on assets (TTM)
2.76%
Return on equity (TTM)
6.32%
Valuation
Price to earnings (TTM)
29.775
Price to revenue (TTM)
2.732
Price to book
1.79
Price to tangible book (TTM)
4.48
Price to free cash flow (TTM)
11.172
Free cash flow yield (TTM)
8.95%
Free cash flow per share (TTM)
295.03%
Growth
Revenue change (TTM)
11.82%
Earnings per share change (TTM)
-464.25%
3-year revenue growth (CAGR)
3.57%
10-year revenue growth (CAGR)
19.52%
3-year earnings per share growth (CAGR)
-5.56%
10-year earnings per share growth (CAGR)
24.45%
What the Analysts think about SUPN
Analyst ratings (Buy, Hold, Sell) for Supernus Pharmaceuticals stock.
Bulls say / Bears say
The U.S. FDA approved Supernus Pharmaceuticals' drug-device combination, Onapgo, for treating Parkinson's disease, potentially leading to significant revenue growth. (reuters.com)
Onapgo demonstrated a significant reduction in daily 'off episodes' for Parkinson's patients compared to a placebo, indicating strong clinical efficacy. (reuters.com)
Supernus anticipates U.S. peak sales of $200 to $300 million for Onapgo, suggesting a substantial positive impact on the company's financial performance. (reuters.com)
StockNews.com downgraded Supernus Pharmaceuticals from a 'strong-buy' to a 'buy' rating, indicating potential concerns about the company's near-term prospects. (marketbeat.com)
Cantor Fitzgerald maintained a 'neutral' rating with a $36.00 price target, suggesting limited upside potential for the stock. (marketbeat.com)
Stephens Investment Management Group LLC reduced its stake in Supernus Pharmaceuticals by 9.3%, possibly reflecting decreased confidence in the company's future performance. (marketbeat.com)
Data summarised monthly by Lightyear AI. Last updated on 10 Jun 2025.
SUPN Financial Performance
Revenues and expenses
SUPN Earnings Performance
Company profitability
SUPN News
AllArticlesVideos
SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE
Business Wire·2 days ago
Supernus Pharma to acquire Sage Therapeutics in up to $795 million deal
Reuters·4 days ago
Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio
GlobeNewsWire·4 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Supernus Pharmaceuticals stock?
Supernus Pharmaceuticals (SUPN) has a market cap of $2.1B as of June 20, 2025.
What is the P/E ratio for Supernus Pharmaceuticals stock?
The price to earnings (P/E) ratio for Supernus Pharmaceuticals (SUPN) stock is 29.78 as of June 20, 2025.
Does Supernus Pharmaceuticals stock pay dividends?
No, Supernus Pharmaceuticals (SUPN) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Supernus Pharmaceuticals dividend payment date?
Supernus Pharmaceuticals (SUPN) stock does not pay dividends to its shareholders.
What is the beta indicator for Supernus Pharmaceuticals?
Supernus Pharmaceuticals (SUPN) has a beta rating of 0.74. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.